For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 45,904 | 25,268* | 50,334 | - |
| Selling, general and administrative | 23,620 | 16,703* | 17,362 | - |
| Total operating expenses | 69,524 | 41,970 | 67,696 | - |
| Loss from operations | -69,524 | -41,970* | -67,696 | - |
| Interest income | 6,893 | 7,558* | 6,412 | - |
| Interest expense | 844 | 867* | 917 | - |
| Other income (expense) | 22 | -30* | -18 | - |
| Total other income (expense), net | 6,071 | 6,661* | 5,477 | - |
| Loss before income taxes | -63,453 | -35,309* | -62,219 | - |
| Income tax expense | 51 | 130* | 102 | - |
| Net loss | -63,504 | -35,439 | -62,321 | -55,247 |
| Foreign currency translation adjustments | - | - | - | -15 |
| Unrealized gain on marketable securities | - | - | - | -247 |
| Total other comprehensive loss | - | - | - | -262 |
| Comprehensive loss | - | - | - | -55,509 |
| Basic EPS | -1.65 | -0.993 | -1.77 | -1.58 |
| Diluted EPS | -1.65 | -0.993 | -1.77 | -1.58 |
| Basic Average Shares | 38,491,433 | 35,683,706 | 35,178,691 | 35,024,592 |
| Diluted Average Shares | 38,491,433 | 35,683,706 | 35,178,691 | 35,024,592 |
Disc Medicine, Inc. (IRON)
Disc Medicine, Inc. (IRON)